QT VASCULAR ANNOUNCES 24-MONTH ANGIOGRAPHIC DATA FOR CHOCOLATE HEART™ DRUG-COATED CORONARY BALLOON

SINGAPORE, 21 June 2017 – QT Vascular Ltd., together with its subsidiaries (**"QT Vascular" or the "Company"**), announced today it has received angiographic data from 24-month follow-up of patients with *De Novo* lesions treated with Chocolate Heart™ as a standalone therapy. The initial six-month results were announced on 5 January 2016.

Chocolate Heart™ is the drug-coated version of the Company's Chocolate® coronary balloon that is commercially available in the United States. The Company has added a proprietary coating formulation with paclitaxel to the Chocolate® coronary balloon to reduce the incidence of repeat procedures. This combination of the Chocolate® technology and the therapeutic agent is intended to allow certain patients to be treated with Chocolate Heart™, minimizing the need for a stent.

The First-In-Human study was conducted at CECANOT Hospital in Santo Domingo, Dominican Republic. The follow-up included 14 patients treated with Chocolate Heart™ that would have otherwise received a stent. The results show no late lumen loss (negative 0.06) and no further interventions were needed at two years. "I would like to change my approaches for coronary arteries and use more Drug-Coated Chocolate® Balloons; I believe it may be the best for my patients." said Carlos H. Garcia-Lithgow, MD, Head of interventional Cardiology, CECANOT, Santa Domingo, Dominican Republic and the Study Principal Investigator.

"These are impressive 24-month angiographic results showing negative late loss which basically means the arteries stayed wide open after two years. When compared to published data on drug-eluting coronary stents (0.1– 0.3mm of late lumen loss at 9-13 months); these data suggest that permanent implants could be avoided in a subset of patients. This is a small study and if the data is confirmed in larger studies, it could lead to a change in the way coronary lesions are treated," stated Alexandra Lansky, MD, Professor of Medicine, Heart and Vascular Clinical Research Program Yale University School of Medicine.

"We are delighted with the angiographic results of Chocolate Heart™ showing maintenance of patency at two years," stated Eitan Konstantino, PhD, CEO of QT Vascular. "Those patients are doing well without a stent in their heart and this is exactly what we are here for."

Chocolate Heart™ is not approved for use in the United States and CE mark does not constitute such approval.

~~ End ~~

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

For more information, please visit the Company's website at www.qtvascular.com

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.*

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.